Enter Your Email Address to Receive a
Copy of MedicExhange Member Demograhpics

EDAP, the global leader in therapeutic ultrasound, reported that its Ablatherm-HIFU technology and new Sonolith i-move lithotripter were featured at the 25th Annual European Association of Urology (EAU) Conference.

The EAU conference is the world's premier urology event. The conference provided EDAP with the opportunity to showcase its minimally invasive technology, highlighted by the official launch of its latest innovation, the Sonolith i-move lithotripter.

Marc Oczachowski, EDAP's Chief Executive Officer commented, "Despite lower attendance than usual at the conference due to the effects of the Icelandic volcano, we are pleased with the strong interest and feedback we received from urologists related to our innovative Sonolith i-move lithotripter and its unique infrared stereo-vision ultrasound system designed to automatically track urinary stones. We will continue to aggressively promote and market the device to the urological community as our Sales and Marketing team will focus their efforts on reaching out to those physicians who were unable to attend the EAU event."

During EAU, EDAP also highlighted the growing clinical results and physician experiences with Ablatherm-HIFU. Key opinion leaders and long-term Ablatherm users from Germany and France presented updated patient data from EDAP's @-Registry centralized database. This comprehensive registry compiles valuable long-term data on Ablatherm-HIFU that continues to demonstrate treatment benefits and validate the technology as a minimally invasive solution for localized prostate cancer.

The growing adoption of high-intensity focused ultrasound (HIFU) was further supported by recent updates to EAU guidelines that integrate the use of HIFU into a recommended treatment option for the management of prostate cancer in patients with recurrence of cancer after radiotherapy. This update is a significant endorsement for HIFU and a great step forward for the technology as 30% of patients treated with radiotherapy show a recurrence of their cancer and are unable to undergo additional radiotherapy sessions. HIFU offers a valuable solution that addresses the recurrence of cancer and can also be repeated. In addition, EAU also acknowledged that HIFU's focal therapeutic approach strongly positions the therapy for broader management of localized prostate cancer.

Marc Oczachowski, continued, "These recommendations and updated guidelines from EAU confirm high-intensity focused ultrasound (HIFU)'s growing credibility and acceptance as a minimally invasive and valuable solution for patients with prostate cancer. We are confident that Ablatherm-HIFU is positioned as the optimal therapy for those patients who have failed initial radiotherapy treatment. We will continue to pursue our efforts to grow the adoption of HIFU technology and develop our strong @-registry patient database to validate HIFU effectiveness."

The EAU organization officially launched an e-learning portal called "EAU Education Online" that includes an on-line treatment simulation using the Ablatherm-HIFU device. This innovative e-learning fast-track program was presented during a dedicated workshop and is part of a partnership between EDAP and the EAU to increase interest and make urologists more comfortable with using Ablatherm-HIFU technology.

Source: EDAP TMS SA

Discuss more about ultrasound in the ultrasound user group.